For instance, troglitazone, a drug that was recalled from the US market due to DILI and now used as a prototypical iDILI inducer, has been proposed to cause hepatotoxicity via (1) the formation of reactive quinones and quinone methides leading to subsequent GSH depletion [42], (2) the depletion of ATP and cytochrome c release causing apoptosis [43], and (3) BSEP inhibition by the parent compound and troglitazone sulphate metabolite leading to cholestasis [81] (Table 1). This evidence concerns the gene ABCB11 and cholestasis.